SCHEMBL87291

SCHEMBL87291

C=CC(=O)Oc1ccc2c(c1)C(=O)c1c(ccc3ccccc13)OC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TYMS P04818 1/20 0.38
MEN1 O00255 2/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ROCK2 O75116 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAOA P21397 3/20 0.36
MAOB P27338 3/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL86953 0.82 MAPT (0.62) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL11602558 0.77 ALDH1A1 (0.50) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL86955 0.75 MAPT (0.39) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL23963396 0.72 MAOA (0.51) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL12216194 0.72 MAPT (0.49) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL18328878 0.70 CYP19A1 (0.42) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL15292034 0.69 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL10922096 0.69 MAPT (0.70) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL87534 0.68 GRM5 (0.41) ALDH1A1SMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL12269873 0.68 CYP19A1 (0.40) MAPTKMT2ATYMSMEN1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2053095-B1 Ink composition and inkjet recording method using the same FUJIFILM CORP (JP) 2014-03-26 EP disclosed
US-8129447-B2 Ink composition and inkjet recording method using the same FUJIFILM CORPORATION (JP) 2012-03-06 US disclosed
US-8129447-B2 Ink composition and inkjet recording method using the same FUJIFILM CORPORATION (JP) 2012-03-06 US disclosed
EP-2053095-A2 Ink composition and inkjet recording method using the same Fujifilm Corporation (JP) 2009-04-29 EP disclosed
US-20090087575-A1 INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2009-04-02 US disclosed
US-20090087575-A1 INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090087575-A1 INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME RB1, IK, NOX1 MAPT 2087/4885ALDH1A1 440/4885SMN1; SMN2 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.